Drugs / Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07638813 | Jul 2026 → Oct 2027 expected | frontotemporal dementia | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07638813 ↗ |
| Known as | MSC-Exos | “Participants randomized to the low-dose group will receive intranasal spray of human umbilical cord mesenchymal stem cell-derived exosomes (MSC-Exos), 1 mL per administration...” NCT07638813 ↗ |
| Route | Intranasal | “receive intranasal spray” NCT07638813 ↗ |